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Abstract
Background: Neurofibrillary tangles (NFT), a cardinal neuropathological feature of Alzheimer’s disease (AD) that is
highly correlated with synaptic loss and dementia severity, appear to be partly attributable to increased
phosphorylation of the microtubule stabilizing protein tau at certain AD-related residues. Identifying the kinases
involved in the pathologic phosphorylation of tau may provide targets at which to aim new AD-modifying
treatments.
Results: We report results from a screen of 572 kinases in the human genome for effects on tau
hyperphosphorylation using a loss of function, high-throughput RNAi approach. We confirm effects of three kinases
from this screen, the eukaryotic translation initiation factor 2 a kinase 2 (EIF2AK2), the dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1A (DYRK1A), and the A-kinase anchor protein 13 (AKAP13) on tau
phosphorylation at the 12E8 epitope (serine 262/serine 356). We provide evidence that EIF2AK2 effects may result
from effects on tau protein expression, whereas DYRK1A and AKAP13 are likely more specifically involved in tau
phosphorylation pathways.
Conclusions: These findings identify novel kinases that phosphorylate tau protein and provide a valuable reference
data set describing the kinases involved in phosphorylating tau at an AD-relevant epitope.
Background
Alzheimer’s disease (AD) is a secondary tauopathy, gen-
erally thought to result from the upstream effects of
toxic amyloid aggregates. While there are a growing
number of amyloid-modifying therapeutics in clinical
trials, targeting amyloid alone may not be sufficient to
mitigate the cognitive deficits that occur during the full
course of AD[1]. Other targets, such as the tau and apo-
lipoprotein E proteins, are thus being investigating for
additional therapeutic development. However, the pro-
teins through which amyloid signals to promote tau
pathology in AD are a critical missing link that must be
connected to facilitate the development of tau-modifying
AD treatments.
In AD, tau protein becomes hyperphosphorylated and
aggregates into paired helical filaments (PHF), the main
component of NFTs [2-7]. Indeed, altered tau protein
function has emerged as a key factor in many neurode-
generative diseases, including AD[8,9]. Tau functions as
a microtubule organizing protein that increases microtu-
bule stability by suppressing dynamic instability[10].
Hyperphosphorylation of tau protein is thought to lead
to microtubule instability, neurofibrillary tangle forma-
tion, and loss of a functional microtubule cytoskeleton,
contributing to neuronal cell dysfunction and cell death.
In Alzheimer’s disease, sequential hyperphosphorylation
of tau protein on multiple amino acids correlates with
the severity of NFT pathology in affected brain regions
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associated with tau dysfunction and neurodegeneration
[12]. Phosphorylation of tau protein on serine 262 has
been demonstrated to significantly reduce the affinity of
tau protein for microtubules[13] and this serine is
hyperphosphorylated early in progression of disease
pathology, before mature NFTs form[11]. Thus,
increased ser262 phosphorylation is an important initial
step in the pathological progression to cytoskeletal dys-
function and NFT formation in Alzheimer’sd i s e a s e ,
although full neurodegenerative effects likely require
hyperphosphorylation of multiple sites[14]. Identifying
the kinases involved in ser262 hyperphosphorylation will
increase our understanding of the mechanisms causing
tau and cytoskeletal dysfunction in AD, and could pro-
vide new targets for the discovery of tau-modifying AD
treatments.
In vitro, numerous Ser/Thr kinases phosphorylate tau
protein[15]. Kinases reported to phosphorylate tau on
ser262, either directly or indirectly, include calcium/cal-
modulin dependent protein kinase 2[16,17], protein
kinase A[18], microtubule affinity regulating kinase 2
[19], phosphorylase kinase[20], and glycogen synthase
kinase 3b [21,22]. However, the in vivo role of these
kinases in the etiology of neurofibrillary tangle forma-
tion remains unclear.
We report the use of a high-content siRNA based
screening strategy, surveying 572 kinases throughout the
human genome, to identify the kinases involved in
ser262 tau phosphorylation. After screening validated
siRNAs, we identified candidate kinases that either
increased or decreased pS262 tau levels. We provide evi-
dence that the eukaryotic translation initiation factor 2
a kinase 2 (EIF2AK2), dual-specificity tyrosine-(Y)-phos-
phorylation regulated kinase 1A (DYRK1A), and a-
kinase anchor protein 13 (AKAP13) proteins contribute
to phosphorylation of tau at the 12E8 epitope (pS262/
pS356).
Results
High-content siRNA screen of the kinome
To identify the kinases that are important in AD rele-
vant pathologic phosphorylation of tau protein, we
developed a cell-based, high-throughput immunofluores-
cence assay for the rapid detection and quantitation of
both total tau and 12E8 tau (pS262 and pS356) protein
expression. The assay uses an H4 neuroglioma cell line
engineered to overexpress four repeat tau (4R0N). We
confirmed that the assay was sensitive to changes in
both total tau protein levels and phosphorylated tau
protein levels using siRNA directed at the tau (MAPT)
mRNA (Figure 1A). Importantly, we are able to achieve
>95% siRNA transfection efficiency with the H4-tau cell
line as assessed by transfection with a lethal siRNA
(data not shown). The accuracy of the immunofluores-
cence quantitation was confirmed by measuring the
effects of the MAPT siRNA on total and phosphorylated
tau protein levels using western analysis (Figure 1B). We
next tested if reduced 12E8 tau levels could be detected
using siRNA directed against microtubule affinity regu-
lating kinase 2 (MARK2), which has previously been
shown to phosphorylate tau protein on serine 262[19].
The MARK2 siRNA, which reduced MARK2 expression
>95% at the mRNA level, led to a 26% reduction in
12E8 phosphorylated tau (p = 0.029 for three replicates)
and to an insignificant change in total tau protein
expression (Figure 2). This result demonstrates that this
immunofluorescence assay can detect changes to phos-
phorylated tau protein independently of significant
changes in total tau protein levels.
siRNA screening results
Following assay validation, we screened the validated
kinome siRNA library (Qiagen) for kinases that affect
tau phosphorylation status. Cataloging of kinases from
the human genome has identified at least 518 kinases
[23,24]. This library contains siRNAs to 572 known and
predicted kinases. Two siRNAs per target kinase were
screened in triplicate for a total of 3,432 target siRNAs
screened. Standard paired, two-tailed T-tests were used
to determine significant effects relative to non-silencing
siRNA controls, which were present in triplicate on
each plate. All siRNA screening data are presented as
Additional File 1.
To identify potential therapeutic targets that might
modify the course of tau phosphorylation and dysfunc-
tion in AD, we first identified those kinases that signifi-
cantly affected the ratio of 12E8 tau to total tau. The
ratio of 12E8 tau/total tau could be altered in several
ways, either by changes to phosphorylated tau, by
changes to total tau, or by a combination of changes to
both phosphorylated tau and total tau. For this reason
we initially identified siRNAs that significantly reduced
12E8 tau levels with no significant effects on total tau
levels relative to non-silencing siRNA controls. Of these
kinases, we identified those that significantly affected the
ratio of 12E8 tau/total tau relative to the non-silencing
siRNA control. These kinases are listed in Table 1 and
are candidate kinases acting in specific tau phosphoryla-
tion pathways.
Notably, the microtubule affinity regulating kinase 2
(MARK2) protein, which has been shown to phosphory-
late serine 262 of tau protein[19], showed the largest
reductions in the ratio of 12E8 tau/total tau when
knocked down (69% of control; p = 0.012). This is com-
parable to the effects seen in our validation assays with
MARK2 siRNA, suggesting that the screening assay is
performing as expected. Because this kinase is already
well known to be a serine 262 tau kinase, we did not
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Page 2 of 10Figure 1 Quantitative immunofluorescence detection of reductions in 12E8 tau and total tau protein levels using MAPT siRNA. Shown
in A is reduction of both pS262 tau and total tau levels using an siRNA directed at the tau transcript (all splice variants). Using this siRNA, pS262
tau and total tau levels are reduced to 45% and 54% of control values, respectively, following 4 days of transfection with siRNA. pS262 tau is
visualized in red. Total tau is in green. Blue staining represents DAPI stained nuclei. Note that significant total tau expression remains following
siRNA treatment, likely resulting from the extremely high constitutive levels of tau expression in this cell line. Shown in B is secondary
quantitation of the MAPT siRNA effects on 12E8 and total tau using western analyses. Results support the immunofluorescence quantitation
shown in A. Representative images are shown. Percent control numbers (± SD) in A represent the average of three independent assays.
Westerns in B were performed in triplicate. NS refers to the non-silencing siRNA control.
Figure 2 Quantitative reduction of 12E8 tau with siRNA against MARK2. Shown in A is detection of pS262 tau and total tau levels
following transfection with MARK2 siRNA. Our quantitative assay detects significant reduction of pS262 tau using siRNA directed at the
microtubule affinity regulating kinase 2 (MARK2) gene (red panels; p = 0.029 for three replicates). MARK2 siRNA has no effect on the overall
levels of total tau protein (green panels), demonstrating that this assay can specifically detect reductions in pS262 tau. Representative images are
shown. Percent control numbers represent the average of three independent assays. NS refers to the non-silencing siRNA control. In B, qRT-PCR
results confirmed >95% knockdown of MARK2 mRNA relative to non-silencing siRNA control (NS).
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chose to validate two additional candidates. These were
A-kinase anchor protein 13 (AKAP13) and dual specifi-
city tyrosine phosphorylation regulated kinase 1A
(DYRK1A), which were selected both for the significance
of the effect (based on p values for the ratio of 12E8/
total tau) and for the known biology of these candidates
(see Discussion). The gene encoding DYRK1A is located
within the Down Syndrome critical region (DSCR) on
chromosome 21. Screening results showed 12E8 tau
levels to be reduced to 77 ± 5% of control (p = 0.017),
total tau to be 85 ± 10% of control (p = 0.127), which
lead to a significant reduction in the ratio of 12E8 tau/
total tau to 86 ± 4% of control (p = 0.023; Table 1 and
Figure 3A). We confirmed via western analyses that
DYRK1A is required for efficient phosphorylation of
12E8 tau. We retransfected our cell line with siRNA tar-
geting DYRK1A and quantitated effects on 12E8 tau and
total tau levels via western (Figure 3B). Results con-
firmed that DYRK1A is required for maintaining normal
levels of 12E8 tau. The DYRK1A siRNA reduced
DYRK1A protein expression by over 60%, causing a
nearly 40% reduction of 12E8 tau compared to the non-
silencing siRNA control. DYRK1A siRNA had no signifi-
cant effect on total tau levels in this assay. Interestingly,
the effects on tau phosphorylation are strikingly larger
than observed in the fluorescence screening assay. Rea-
sons for this are unclear, however it suggests that the
screening assay may be underestimating the magnitude
of effects on tau phosphorylation. Since DYRK1A is a
proline- directed serine/threonine kinase and serine 262
is a non-proline directed site on tau, these effects of
DYRK1A may result from indirect effects through addi-
tional kinases (see Discussion).
Tests of AKAP13 showed that this protein kinase A
(PKA) associated protein is also involved in 12E8 tau
phosphorylation. Screening results showed 12E8 tau
levels to be reduced to 74 ± 7% (p = 0.023) of control
non-silencing siRNA samples, total tau levels to be 93 ±
7% (p = 0.223) of control, leading to a reduction in the
ratio of 12E8 tau/total tau to 79 ± 9% (p = 0.054) of con-
trol (Table 1 and Figure 4A). Because this phosphoryla-
tion profile resembled that of MARK2, a confirmed S262
tau kinase, we proceeded to confirm these effects via sec-
ondary measures. Western results demonstrated a role
for AKAP13 in maintaining 12E8 tau phosphorylation
levels. The AKAP13 siRNA reduced AKAP13 protein
expression to undetectable levels (Figure 4B), causing a
nearly 50% reduction of 12E8 tau. AKAP13 siRNA had
no significant effect on total tau levels in this assay.
Some drosophila models have shown that increased
tau expression can lead to neurodegeneration, albeit in
the absence of NFT pathology[25]. Thus the potential
for a tau therapeutic that affects both phosphorylated
and total tau levels cannot at this point be diminished.
We therefore performed a second analysis of the data to
Table 1 Candidate kinases that phosphorylate 12E8 tau
12E8 Tau/Control Total Tau 12E8 Tau/Total Tau
Gene Name Cell Count Average St Dev p value Average St Dev p value Average St Dev p value
MARK2 453 0.672 0.044 0.006 0.979 0.039 0.451 0.687 0.060 0.012
PAK3 170 0.803 0.067 0.036 1.112 0.197 0.429 0.730 0.072 0.023
PAK2 287 0.726 0.081 0.028 0.986 0.101 0.831 0.741 0.109 0.054
ADCK5 280 0.716 0.104 0.042 0.934 0.094 0.351 0.765 0.069 0.028
AKAP13 181 0.738 0.069 0.023 0.929 0.070 0.223 0.797 0.086 0.054
LOC55971 152 0.836 0.035 0.014 0.982 0.019 0.241 0.852 0.042 0.026
PLK2 335 0.774 0.087 0.046 0.906 0.114 0.289 0.856 0.052 0.040
DYRK1A 316 0.774 0.051 0.017 0.848 0.104 0.127 0.860 0.038 0.023
MAK 393 1.109 0.021 0.012 0.919 0.037 0.063 1.209 0.054 0.021
ITK 285 1.124 0.036 0.027 0.887 0.059 0.079 1.273 0.118 0.057
PIM1 409 1.248 0.097 0.047 0.965 0.105 0.624 1.297 0.080 0.023
RAGE 397 1.305 0.106 0.038 0.960 0.088 0.511 1.361 0.053 0.007
ITPK1 399 1.324 0.119 0.042 0.930 0.084 0.285 1.424 0.024 0.001
CKB 223 1.537 0.143 0.023 1.065 0.146 0.523 1.454 0.138 0.030
PFKM 375 1.305 0.096 0.032 0.888 0.112 0.227 1.476 0.082 0.010
DGKB 440 1.350 0.096 0.024 0.921 0.163 0.488 1.489 0.200 0.052
SPHK2 333 1.792 0.282 0.040 1.074 0.121 0.399 1.664 0.114 0.010
A list of kinases affecting 12E8 tau phosphorylation. Shown are the most significant effectors of 12E8 tau phosphoylration emerging from a high-content siRNA
screen of the complete “kinome.” Indicated in the columns from left to right are, the Gene Name, the cell counts (which refers to the number of cells in the well
following transfection and is and indicator of potential siRNA toxicity), and then the average fold effect, standard deviation, and p value for 12E8 tau, total tau,
and the ratio of 12E8 tau/total tau. For a reference on cell counts, non-siliencing s iRNA control cell counts range from ~330-380, depending on the individual
plates in the assay. This tabel contains only those siRNAs that affect pS262 tau/total tau through significant effects on pS262 tau alone. Total tau levels were
selected to be insignificantly effected (p > 0.05), although some candidates clearly show a strong trend toward significant reductions in total tau.
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Page 4 of 10identify those kinases that significantly affected both
12E8 and total tau levels simultaneously. To identify
those candidates, we pulled out kinases that had statisti-
cally significant effects on both total tau levels and 12E8
tau levels relative to controls, irrespective of the result-
ing effects on the ratio of 12E8 tau/total tau. These are
presented in Table 2. Interestingly, two siRNAs to the
eukaryotic translation initiation factor 2 a kinase 2
(EIF2AK2) gene significantly reduced 12E8 and total tau
levels (Figure 5 and Table 2). These siRNAs reduced
12E8 tau levels to 61 ± 8% (p = 0.012) and 72 ± 7% (p
= 0.018) of non-silencing siRNA controls and reduced
total tau levels to 65 ± 10% (p = 0.026) and 71 ± 8% (p
= 0.025) of control values, respectively. The comparable
eductions of both phosphorylated and total tau levels
led to no change in the ratio of 12E8 tau/total tau.
To confirm these screening results for EIF2AK2,w e
retransfected our cell line with EIF2AK2 siRNA. Wes-
tern blotting results confirmed that EIF2AK2 is required
for maintaining normal levels of 12E8 tau and total tau
Figure 3 DYRK1A is required for efficient phosphorylation of 12E8 tau. Shown in A are results of siRNA screening for DYRK1A siRNA. 12E8
tau is shown in red and total tau is shown in green (see Experimental Methods). For B, H4 cells overexpressing four repeat tau (4R0N) were
transfected with siRNA targeting the DYRK1A transcript. Silencing of DYRK1A was confirmed with anti-DYRK1A antibody (top panel). Percent
control values represent the average of three independent siRNA transfections and westerns. In A and B, NS refers to the nonsilencing control.
Figure 4 AKAP13 is required for efficient phosphorylation of 12E8 tau. Shown in A are results of siRNA screening for AKAP13 siRNA. 12E8
tau is shown in red and total tau is shown in green (see Experimental Methods). For B, H4 cells overexpressing four repeat tau (4R0N) were
transfected with siRNA targeting the AKAP13 transcript. Silencing of AKAP13 was confirmed with anti-AKAP13 antibody (top panel). Percent
control values represent the average of three independent siRNA transfections and westerns shown. In A and B, NS refers to the non-silencing
control.
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Page 5 of 10protein. EIF2AK2 siRNA treatment reduced EIF2AK2
levels to 5% of control non-silencing siRNA, leading to
a reduction of 12E8 tau levels to 14% of control non-
silencing siRNA (Figure 5B). Total tau levels were
reduced to 47% of control values. Again, this effect is
strikingly larger than revealed in the immunofluores-
cence screening assay, providing additional confirmation
that the assay is likely to be underestimating the true
magnitude of the effects of some gene candidates.
Discussion
High-throughput, high-content siRNA screening in
neurodegenerative diseases
We report the combination of a high-throughput survey
of the entire kinome with a new assay approach to under-
stand a critical component of tau pathology, and provide
new targets for the discovery of tau-modifying AD treat-
ments. We have developed a sensitive and specific assay
for the detection of hyperphosphorylated tau protein on
an AD-relevant site. The assay is not only amenable to
additional tau phosphorylation sites, but also to those
identifiable cell-based endpoints related to other neuro-
degenerative diseases. Imaging technology has only
recently become available to enable these high-content
analyses. However, with a persistent need for the identifi-
cation of novel drug targets to treat increasingly common
neurodegenerative diseases, RNA interference screening
technology now provides a promising approach.
EIF2AK2 and DYRK1A as important mediators of
AD-related tau hyperphosphorylation
The cell line used in these studies overexpresses 4R0N
tau protein. This is technically necessary to achieve
Table 2 Candidate kinases affecting total tau and 12E8 tau expression
12EB Tau/Control Total Tau 12E8 Tau/Total Tau
Gene Name Cell Count Average St Dev p value Average St Dev p value Average St Dev p value
EIF2AK2 217 0.606 0.075 0.012 0.647 0.102 0.026 0.962 0.237 0.806
EIF2AK2 318 0.719 0.069 0.018 0.706 0.082 0.025 1.038 0.257 0.822
CDKL1 398 0.852 0.032 0.015 0.761 0.085 0.040 1.132 0.157 0.281
DCK 363 1.068 0.015 0.017 0.701 0.051 0.010 1.530 0.107 0.013
DGKQ 406 1.119 0.042 0.039 0.805 0.059 0.029 1.394 0.111 0.026
PFKFB3 458 1.204 0.046 0.016 0.813 0.029 0.008 1.483 0.088 0.011
ERK8 466 1.234 0.063 0.024 0.807 0.009 0.001 1.528 0.084 0.008
STK19 347 1.334 0.103 0.030 0.654 0.115 0.035 2.065 0.231 0.015
PRKG2 413 1.384 0.152 0.048 0.721 0.107 0.046 1.959 0.412 0.056
MAP2K1IP1 436 1.393 0.052 0.006 0.831 0.048 0.026 1.679 0.123 0.011
Kinases that affect bioth 12E8 tau and total tau levels. Shown are those kinases that affect total tau levels and 12E8 tau levels, irrespective of significant effects
to the ratio of 12E8 tau/total tau. Columns are labeled as in Table1.
Figure 5 EIF2AK2 is required for maintenance of normal 12E8 tau levels and total tau expression. Shown in A is the kinome library
screening result for EIF2AK2 siRNA. Effects on 12E8 tau (red) and total tau (green) are shown to the right of each image. In B, triplicate western
analyses confirm that EIF2AK2 is required for maintenance of tau and 12E8 tau levels. The EIF2AK2 siRNA reduced expression of EIF2AK2 by 95%,
resulting in an 85% reduction of 12E8 tau and a greater than 50% reduction of total tau levels. NS is the non-silencing control siRNA.
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for detection of modulation of phosphorylation status.
Because of this overexpression there is the possibility of
creating a significant cytoplasmic pool of tau protein
that is not bound to microtubules. This raises the possi-
bility that some phospho-epitopes that are normally pro-
tected (via microtubule binding or interactions with
other proteins at physiologic concentrations) may be
exposed and phosphorylation pathways that do not nor-
mally regulate tau would have an effect in this assay.
However, the identification of MARK2 as a significant
pS262 tau phosphorylator (Table 1) suggests that tau
regulatory pathways are functioning on the 12E8 epitope
in this cell line. Nevertheless, the true applicability of
the kinases that we identify here will emerge only after
subsequent follow up studies in neuronal cell lines and
in vivo in animal models of AD and of tauopathies.
Both the eukaryotic translation initiation factor 2 a
kinase 2 gene (EIF2AK2) and the dual specificity tyro-
sine phosphorylation regulated kinase 1A gene
(DYRK1A) have been implicated previously in neurode-
generation in AD. Polymorphisms within the eukaryotic
translation initiation factor 2 a kinase 2 (EIF2AK2) gene
have been genetically associated with AD[26]. In addi-
tion, EIF2AK2 has been shown to be activated in AD
brain[27,28] and has been implicated in neuronal apop-
tosis resulting from toxic b-amyloid peptides[28].
EIF2AK2 has also been implicated in the extrastriatal
neurodegeneration of Parkinson’s disease and Hunting-
ton’s disease[29]. In our study, two siRNAs that reduced
EIF2AK2 protein expression by 95% caused a significant
reduction of pS262 tau levels and a lesser but significant
reduction in total tau levels (Table 2). These findings
suggest an important role for EIF2AK2 in the expression
of total and 12E8 phosphorylated tau protein. Moreover,
the comparable effects seen for total tau and 12E8 tau
suggest the possibility that EIF2AK2 may be required
for the maintenance of multiple forms of phosphory-
lated tau, in addition to 12E8 tau. Deciphering the
mechanisms through which this regulation occurs will
require additional experimentation.
Polymorphisms within the DYRK1A locus also have
been associated with AD in some AD patient popula-
tions[30]. Moreover, DYRK1A has been implicated in
phosphorylation of tau protein on threonine 212, serine
202, and serine 404[31,32]. In this work we demonstrate
a role for DYRK1A in the phosphorylation of tau pro-
tein on the 12E8 epitope, independent of significant
effects on total tau protein expression. Interestingly,
DYRK1A is a proline- directed serine/threonine kinase.
Serine 262 is not a proline-directed phosphorylation site
o nt a u .O n ep o s s i b l es c e n a r i oi st h a tD Y R K 1 Ae f f e c t s
on S262 could occur through activities of additional
kinases downstream of DYRK1A function. Presumably,
silencing of those kinases would also affect 12E8 tau
levels in our assay and strong candidates for down-
stream kinases through which DYRK1A may be signal-
ing are those additional kinases in Table 1. Ongoing
work is directed at identifying the additional signaling
components involved in mediating the effects of
DYRK1A on 12E8 tau phosphorylation and at determin-
ing if DYRK1A is capable of directly phosphorylating
tau protein on serine 262/serine 356.
A possible role for AKAP13 in the regulation of tau
phosphorylation
Although it is clear that AKAP13 has significant effects
on 12E8 tau levels in our cell line, the mechanisms
through which this protein may affect tau are unclear.
The AKAP13 protein is an ~320 kD protein that func-
tions as an anchor protein for the regulatory subunit of
protein kinase A, effectively localizing the PKA holoen-
zyme to discrete locations within the cell. Protein kinase
A has been reported to increase tau phosphorylation in
vitro on the 12E8 epitope under some conditions, such
as in response to the binding of a-synuclein to tau pro-
tein[33]. Additionally, AKAP13, and other members of
the AKAP family, have a Dbl homology (DH) domain
that functions as a guanine nucleotide exchange activa-
tion domain for the Rho/Rac family of GTP binding
proteins. Thus, AKAP13 coordinates a Rho signaling
pathway that ultimately leads to cytoskeletal reorganiza-
tion. In addition, other AKAP family members have
been implicated in regulating synaptic plasticity and
long-term memory formation[34,35]. These combined
observations suggest interesting possibilities wherein
AKAP13 could anchor a signaling complex at the cell
membrane that ultimately regulates tau phosphorylation
and microtubule dynamics in response to extracellular
stimuli. However, direct connections to tau phosphory-
lation based on the currently known functions of
AKAP13 are unclear but certainly worthy of further
study.
Conclusions
One additional implication of our findings is that phos-
phorylation of the 12E8 epitope is likely controlled by
multiple redundant signaling pathways. This conclusion
is supported by the fact that silencing of no single
kinase fully blocked 12E8 tau phosphorylation. In addi-
tion, the complexity of these signaling pathways is also
evident in the observation that knockdown of multiple
kinases leads to significant increases in 12E8 tau levels
(Table 1). When coupled with recent findings showing
that phosphorylation of tau at multiple sites appears to
be required for neurotoxicity of tau[14], it is becoming
clear that the regulatory pathways controlling cellular
tau function and dysfunction in disease are complex.
Our results were generated in a cell line that
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Page 7 of 10overexpresses four repeat tau protein, a non-physiologi-
cal condition. However, if in subsequent experiments
these results extrapolate to mammalian brain, it would
suggest that a therapeutic strategy to decrease tau
hyperphosphorylation in AD and other tauopathies may
require the simultaneous modulation of several phos-
phorylation sites. This is one reason why candidate tar-
gets that reduce total tau levels, such as EIF2AK2, are
appealing since they are likelyt os i m u l t a n e o u s l ya f f e c t
multiple phosphorylation sites. Untangling the complex
regulatory networks of tau hyperphosphorylation is a
daunting task. However, our results provide an impor-
tant first step in defining the scope of kinases and asso-
ciated proteins that may be involved in phosphorylating
tau on a site highly relevant to tau dysfunction, tau
pathology, and AD. Further work remains to determine
the complex pathways through which the kinases identi-
fied here may interact to control tau phosphorylation
levels.
Methods
Generation of 4R0N tau overexpressing H4 cell line
The Human H4 neuroglioma cell line (ATCC) was
transfected with a 4R0N tau construct in pcDNA3.1.
Following positive selection using geneticin (Invitrogen),
individual clones were isolated and screened for tau
expression using immunocytochemistry with a rabbit
anti-tau antibody (Dako). A single stable tau overexpres-
sing cell line was selected for subsequent siRNA studies.
Cells were maintained in Dulbecco’s Modified Eagle
Medium (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 1% penicillin-streptomycin,
geneticin (0.25 mg/ml), and 2 mM L-Glutamine (Invi-
trogen). Cells were split 1:10 at 90% confluency, twice a
week.
High Throughput siRNA Kinome Screen
Preparation of siRNA library plates
Chemically synthesized siRNA (18.6 μg) from Qiagen’s
validated human kinase siRNA Set 2.0 were printed into
96-well black clear bottom plates (Corning #3904) using
aB i o M e kF X( B e c k m a nC o u l t er). Printed plates were
then foil sealed and stored at -80°C until use.
High Content siRNA Screening Assay
In order to identify genes involved in modulation of tau
phosphorylation, we developed a high content siRNA
screening assay. Briefly, 4R0N tau overexpressing H4
cells were reverse-transfected with library siRNA and
siLentfect (Bio-Rad) using semi-automated transfection
as follows: Screening plates were thawed and siRNA was
complexed by addition of 50 μl of diluted siLentfect in
OptiMEM (Invitrogen) using a μFill (BioTek) followed
by incubation for thirty minutes at RT. Cells were tryp-
sinized and resuspended in growth media without peni-
cillin-streptomycin and added at a concentration of
3000 cell/well in 50 μl using a μFill followed by incuba-
tion for 5 minutes at room temperature (RT). Assay
plates were incubated at 37°C and 5% CO2, for 96 hours.
Plates were washed twice with 1× Tris-buffered saline
(TBS) (Fisher) and fixed for 15 minutes with4% parafor-
maldehyde (PFA) at RT. Plates were then washed twice
with 1× TBS and incubated with blocking buffer (TBS
with 5% normal goad serum, 0.2% sodium azide, 1%
bovine serum albumin (BSA) and 0.1% NP-40) for 1 hour
at RT. Fixed cells were next incubated with 1 μg/ml of
phospho-tau antibody 12E8 (Elan Pharmaceuticals) at 4°C
overnight. Plates were washed three times with 1× TBS-T
(TBS with 0.1% Tween-20) followed by incubation with
1:200 dilution of rabbit anti-human tau (Dako) for 1 hr at
RT. Plates were then washed twice with 1× TBS-T fol-
lowed by incubation with a secondary antibody cocktail of
2 μg/ml FITC-Goat anti-rabbit IgG, 2 μg/ml Cy5- Goat
anti-mouse IgG (Jackson Immunore search) and 10 μg/ml
Hoechst 33342 (Invitrogen) in blocking buffer for 30 min-
utes at RT. Plates were then washed once with TBS-T fol-
lowed by twice with TBS leaving the last wash in the
plates. Plates were stored at 4°C overnight prior to analy-
sis. Plates were imaged and then analyzed on the INCell
3000 (GE Healthcare). The analysis module (Object Inten-
sity 01) identified each cell by the blue staining of the
nuclei, and measured both red (Cy5) and green (FITC)
intensities in a 4 pixel ring around the nuclei.
Western Blotting
4R0N tau overexpressing H4 cells were reverse-trans-
fected with siLentfect complexed with target siRNA in 6
well plates. Cells were grown for 72 hours at 37°C, 5%
CO2. Cell lysates were prepared using the Complete
Lysis-M, EDTA-free kit (Roche Applied Science) and
quantitated using the BCA protein assay (Pierce). Protein
from lysates (20 μg) were separated by SDS-PAGE and
transferred to nitrocellulose. Membrane was blocked in
5% BSA for one hour at RT. Membranes were probed
w i t hp r i m a r ya n t i b o d yo v e r n i g h ta t4 ° Co nar o c k e r .
Membranes were subsequently washed with TBS-T and
probed with secondary antibody 1:25000 dilution of
HRP-GAM (Jackson Immunoresearch) for forty-five min-
utes. Membranes were further washed and developed
with Super Signal West Femto Maximum Sensitivity Sub-
strate Kit (Promega) and imaged. To test multiple pri-
mary antibodies, membranes were stripped for 15
minutes at RT using ReBlot Plus Mild Antibody Stripping
Solution (Millipore). Membranes were then washed again
for 5 minutes at RT then blocked for one hour in 5%
BSA. Membrane was reprobed overnight at 4°C with an
anti-Tubulin antibody (1:25000; ICN Biomedicals, Inc.).
Antibodies used for detection included anti-tau (1:1000;
Dako) primary antibody, 12E8 antibody (1:7500), anti-
EIF2AK2 (1:1000; Abcam), anti-DYRK1A (1:500; Abcam),
and anti-AKAP13 (1:2000; Bethyl Laboratories, Inc).
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